Group items tagged

In continuation of the NHS Covid vaccine programme, Covid jabs for five and six-year olds will be available at the local vaccination centres or community pharmacies outside of school hours. Following the recent JCVI guidance that recommended all children between 5 and 11 would benefit from a non-urgent offer of the COVID vaccine, the NHS will send invitations to one million families with five and six-year-olds this week. "Invitations being sent to families this week will set out how easy and convenient it is to take up the offer of a vaccine as part of the NHS COVID vaccination programme by booking through the National Booking Service, or visiting their nearest walk-in site," NHS said. Between April 25 and May 1, there are already more than 33,500 children aged five to 11 booked in for their dose of the life-saving vaccine, with a further 50,000 slots still available. Dr Nikki Kanani, GP and Deputy Lead for the NHS COVID-19 vaccination programme, said: "It is great to see so many families already booked in for their children to receive their Covid vaccine this week, helping to protect themselves against potential future waves of the virus.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a second "bivalent" vaccine as a Covid-19 booster. The updated booster vaccine made by Pfizer/BioNTech, targeting two coronavirus variants, has been approved for use in individuals aged 12 years and above. In each dose of the booster vaccine, 'Comirnaty bivalent Original/Omicron', half of the vaccine (15 micrograms) targets the original virus strain and the other half (15 micrograms) targets Omicron (BA.1). Dr June Raine, MHRA chief executive said: "I am pleased to announce that we now have a second approved vaccine for the UK Autumn booster programme. The clinical trial of the Pfizer/BioNTech bivalent vaccine showed a strong immune response against the Omicron BA.1 variant as well as the original strain. Bivalent vaccines are helping us to meet the challenge of an ever-evolving virus, to help protect people against Covid-19 variants. We have in place a comprehensive safety surveillance strategy for all UK-approved Covid-19 vaccines, and this will include the updated booster we approved today."

American global healthcare company, Viatris, has launched a new rapid self-test for qualitative detection of antibodies developed after Covid-19 vaccinations. The firm is going to market the Covid-19 Neutralising IgG Serological self-test, manufactured by PRIMA Lab SA, in the UK market, which would check presence of neutralising antibodies after vaccination. The presence of antibodies indicates that a person has had an immune response to the Covid-19 vaccine, and not that protective immunity has been acquired. The self-test that can be performed easily at home with a small blood sample, delivers results in just 10 minutes and has a recommended retail price of sub £20. After two doses of the Covid-19 vaccine, the self-test has shown a seroconversion rate of 98.3 per cent for the Pfizer vaccine, 98.5 per cent for the AstraZeneca vaccine and 95.2 per cent for the Moderna vaccine. It recommended that the test be performed at least 14 days after completing the vaccination cycle.

The Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday authorised a Covid-19 vaccine for infants as young as six months, opening the door for vaccinating the country's youngest children once the UK's Joint Committee on Vaccination and Immunisation (JCVI) agrees. The regulator authorised the vaccine - made by Pfizer and BioNTech - for children aged six months to four years old, after it was deemed safe and effective based on an ongoing clinical trial involving 4,526 participants. Whether the vaccine is eventually deployed in this age group depends on a recommendation from the JCVI, which advises UK health departments on which shots should be used as part of the national vaccination programme. The vaccine is tailored for use in this age group - it is a lower dose version than the one used in children aged five to 11 years. It is given as three injections in the upper arm, with the first two doses given three weeks apart, followed by a third dose administered at least two months after the second dose.

The Joint Committee on Vaccination and Immunisation (JCVI) has advised booster vaccination to be offered this autumn (2023) for those at higher risk of severe Covid-19 in its interim advice to government on the coronavirus (COVID-19) vaccination programme for 2023. The JCVI also advised that for a smaller group of people, such as those who are older and those who are immunosuppressed, an extra booster vaccine dose in the spring should also be planned for. Professor Wei Shen Lim, Chair of Covid-19 vaccination on the JCVI, said: "The Covid-19 vaccination programme continues to reduce severe disease across the population, while helping to protect the NHS. That is why we have advised planning for further booster vaccines for persons at higher risk of serious illness through an autumn booster programme later this year. We will very shortly also provide final advice on a spring booster programme for those at greatest risk."

The NHS on Sunday (January 30) expanded its Covid-19 vaccination programme to include vulnerable children aged five to 11 years. Eligible children include those with diabetes, immunosuppression, learning disabilities, and other conditions as outlined by the UK Health Security Agency in the Green Book. Besides, children living with someone immunosuppressed will be eligible to get the first dose of the Covid vaccine in line with advice issued by the Joint Committee on Vaccination and Immunisation (JCVI). According to the NHS there are around 500,000 eligible children in the latest cohort. GP and deputy lead for NHS vaccination programme Dr Nikki Kanani, said: "We know vaccines give significant protection against severe illness from Covid - including the omicron variant, so it is important that our youngest and most at-risk get protected.

The NHS on Sunday (January 30) expanded its Covid-19 vaccination programme to include vulnerable children aged five to 11 years. Eligible children include those with diabetes, immunosuppression, learning disabilities, and other conditions as outlined by the UK Health Security Agency in the Green Book. Additionally, children living with someone immunosuppressed will be eligible to get the first dose of the Covid-19 vaccine in line with advice issued by the Joint Committee on Vaccination and Immunisation (JCVI). According to the NHS, there are around 500,000 eligible children in the latest cohort. GP and deputy lead for NHS vaccination programme Dr Nikki Kanani, said: "We know vaccines give significant protection against severe illness from Covid - including the omicron variant, so it is important that our youngest and most at-risk get protected.

Backed by a £22.5 million of government funding, community vaccine champions will tap into their local networks and encourage people in their communities to get vaccinated against the Covid-19. The funding, allocated today (January 13) to 60 councils, will help deliver bespoke projects in these regions, including: In Derby and Newham roving vaccinators and a vaccine bus will visit workplaces, places of worship and local highstreets.Videos shared on social media featuring local sporting stars, TV actors, local community and faith leaders and local NHS staff in Southampton.Developing a community transport to support access to vaccination sites/pop-ups and considering 'Grab a Jab' taxis scheme.As per NHS statistics, over 4.6 million people aged 18 and above remained unvaccinated in the 60 councils, selected to be a part of the Community Vaccine Champions programme. Vaccines minister Maggie Throup said: "Thanks to the pace and scale of our Covid-19 vaccination programme, we are in a much better position than this time last year."

As part of efforts to streamline spending and enhance resource allocation within the healthcare system, the NHS has chosen to cease providing the free vaccinations for all, which were initially introduced in 2020. Approximately 12 million British citizens will not have access to free flu vaccinations and Covid-19 boosters during the upcoming winter, according to NHS. Furthermore, the NHS plans to defer flu vaccine distribution to October, aiming to heighten protection for those aged 65 and older and other eligible groups in the high-risk winter months. However, this has stirred panic among pharmacies, given their advanced planning based on the initial start date of September 1 for vaccinations. On Tuesday (Aug. 8), the Joint Committee on Vaccination and Immunisation (JCVI) released NHS guidelines indicating that Covid-19 booster shots, starting from autumn, will not be provided to individuals aged 50 to 64 who are in otherwise good health. Similar guidance had already been released for flu, rendering 12 million middle-aged Britons ineligible for free jabs, JCVI said. Prior to the pandemic, influenza vaccinations were available to healthy adults aged over 65, alongside children and younger adults with medical conditions. Amidst the pandemic, the distribution of flu vaccinations was expanded to include individuals aged 50 to 64, in alignment with the criteria for Covid-19 boosters.

The General Pharmaceutical Council reiterated its stand on Covid-19 vaccination, saying, "Pharmacists and pharmacy technicians working in all settings across Great Britain should be vaccinated against Covid -19, unless they are medically exempt." In a statement issued today (February 11), it strongly urged all pharmacyprofessionals, students and trainees to get fully vaccinated at the earliest. This reiteration follows the government's announcement on January 31, 2022 that it would not proceed with Covid vaccination as a mandatory condition of deployment for health and care staff providing CQC-regulated services in England. The Council stated that clinical trials have proven the efficacy and safety of Covid vaccines and the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised their use in the UK.

All children aged five to 11 in England will be offered a Covid-19 vaccine, the government said on Wednesday (February 16) - following similar announcements in the rest of the UK. The move, coming nearly two months after British regulators approved Pfizer and BioNTech's shot for use among the age group, sees Britain following the lead of the United States, the European Union and other countries. It has only been vaccinating at-risk under-12s and those who live with immuno-suppressed people, using a lower-dose formulation of the jab that was found to be "safe and effective". However, health secretary Sajid Javid - who has responsibility for England only - said he had now accepted guidance from the Joint Committee on Vaccination and Immunisation, which advises UK health departments, to expand the rollout. "The NHS will prepare to extend this non-urgent offer to all children during April so parents can, if they want, take up the offer to increase protection against potential future waves of Covid-19 as we learn to live with this virus," he said in a statement.

More than 7,000 hospitalisations and deaths in the UK could have been averted in summer 2022 if people had received their recommended COVID-19 vaccine doses, a new study published in The Lancet has revealed. The largest ever study carried out in the UK found that between a third and a half of the UK population had not had the recommended number of COVID vaccinations and boosters by summer 2022. In Northern Ireland, nearly 50 per cent of the population were under-vaccinated, while the proportion of under-vaccinated people in England was 45.7 per cent, 34.2 per cent for Scotland and 32.8 per cent Wales. Researchers from the Health Data Research UK (HDR UK) and the University of Edinburgh analysed the electronic health records of 67 million residents aged 5 and older from across the four countries during June 1 to September 30 2022.

Britain has become the first country to approve a Codiv-19 vaccine that targets both the original and Omicron variant of the virus. Medicines regulator MHRA approved the so-called bivalent vaccine made by US drug company Moderna as a booster for adults. The agency's decision was based on clinical trial data that showed the booster triggered "a strong immune response" against both Omicron (BA.1) and the original 2020 virus, it said. The MHRA also cited an exploratory analysis in which the shot was also found to generate a good immune response against the currently dominant Omicron offshoots BA.4 and BA.5. "The first generation of Covid-19 vaccines being used in the UK continue to provide important protection against the disease and save lives," MHRA chief executive June Raine said in a statement. "What this bivalent vaccine gives us is a sharpened tool in our armoury to help protect us against this disease as the virus continues to evolve."

Britain has approved Novavax's Covid-19 vaccine for use in those 18 years of age and older, the country's medicines regulator said on Thursday (February 3), bringing a fifth coronavirus shot to its roster amidst the rapid spread of the Omicron variant. The vaccine, Nuvaxovid, was approved as a first and second dose as it met the required safety, quality and effectiveness standards, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) said in a statement. The British approval for Nuvaxovid comes days after the drugmaker filed for US authorisation of the vaccine following months of struggles with development and manufacturing problems, and follows a German backing earlier in the day. "We are continuing our vital safety work in monitoring the use of all Covid-19 vaccines, to ensure that their benefits in protecting people against Covid-19 disease continue to outweigh any risks," MHRA chief executive June Raine said.

The government has launched a new campaign over social media and radio today (January 10) to encourage pregnant women to take their first, second and third dose of Covid-19 vaccine. Joined by experts at the Royal College of Obstetricians and Gynaecologists (RCOG) and the Royal College of Midwives (RCM), the campaign highlights the risks of the infection and benefits of vaccination. According to the latest data from the UK Health Security Agency (UKHSA), Covid-19 vaccinations are safe for pregnant women. Department of Health and Social Care (DHSC) chief scientific adviser professor Lucy Chappell, said: "We have extensive evidence now to show that the vaccines are safe and that the risks posed by Covid-19 are far greater," calling upon pregnant women who have yet to have their jabs. The campaign will also run testimonies of pregnant women who have had their jabs.

Britain's Covid booster campaign is set to kick off this September, after the country became the first in the world to approve an Omicron-adapted shot. Around 26 million people in Britain are estimated to be eligible for an autumn Covid-19 booster, having had at least two Covid vaccine doses already, a UK Health Security Agency (UKHSA) spokesperson said. The preference is to deploy what is known as a "bivalent vaccine" that targets both the original virus and the Omicron variant through the autumn campaign, but that will depend on the health regulator (MHRA) approving such shots and the state of vaccine supplies. The UK's Joint Committee on Vaccination and Immunisation (JCVI) has advised boosters should be given to over-50s, individuals in clinical risk groups, frontline workers and care-home staff ahead of the winter, when respiratory viruses are typically at their peak. On Monday (August 15), the MHRA gave Moderna's bivalent shot conditional approval. The endorsement of the vaccine is based on data that showed it produced a marginally better immune response against some Omicron variants, versus the original novel coronavirus - although whether that translates into stronger protection against serious disease is unclear.

Britain has approved a new coronavirus vaccine by the Austrian-French drugmaker Valneva. "An approval has been granted after the Valneva Covid-19 vaccine was found to meet the required safety, quality and effectiveness standards," the Medicines and Healthcare products Regulatory Agency said in a statement on Thursday (April 14), adding: "It is also the first, whole-virus inactivated Covid-19 vaccine to gain regulatory approval in the UK." In vaccines such as Valneva's VLA2001, the virus is grown in a lab and then made completely inactive so that it cannot infect cells or replicate in the body but can still trigger an immune response. It is seen by some as having the potential to win over people wary of some which use new mRNA technology. Valneva CEO Thomas Lingelbach said that "this authorisation could pave the way for the availability of an alternative vaccine solution for the UK population."

Community pharmacies saved nearly 20,000 lives up to autumn 2021 by vaccinating people against the Covid-19, the National Pharmacy Association said based on a National Audit Office (NAO) report released on Friday (February 25). The report, having taken evidence from the NPA, highlighted that community pharmacies and GPs performed far beyond expectations in delivering the Covid-19 vaccine, as 71 per cent of jabs were administered by both healthcare providers till October-end, against an initial assumption of 56 per cent. The report cited UK Health Security Agency figures, which estimated that the programme overall prevented up to 128,000 deaths and 262,000 hospitalisations by September 24 and September 19, respectively. The estimated number is considerably higher, given the pivotal role played by pharmacies in this winter's phase of the vaccination programme, the NPA stated.

As the deadline for the frontline healthcare workers to get fully vaccinated approaches, tens of thousands of NHS staff who have not yet taken the Covid-19 vaccine face termination in just a fortnight. Although it is estimated that the majority of NHS staff have been fully jabbed, health and social care providers in England will soon be needed to ensure that all those working in areas regulated by the Care Quality Commission (CQC), are fully vaccinated against Covid-19 before the April 1, 2022. Those who are exempted from taking the vaccination do not fall under this purview. According to the NHS England guidance around Vaccination as a Condition of Deployment (VCOD) for healthcare workers, all frontline staff must have had both the doses by April 1, meaning that by February 3 the first must have been administered and the second by March 31. All unvaccinated frontline workers will be called into formal meetings from February 4 and given a warning of dismissal. Notices will then be issued from that day, with March 31 marking the end of the notice period

A new study has revealed that the risk of death from COVID-19 decreases significantly after vaccination, but this protection diminishes after six months, providing evidence for continued booster doses. Researchers from the UK Health Security Agency (UKHSA), who analysed more than 10 million cases of COVID-19 in adults in England between May 2020 and February 2022, found a clear association between vaccination and reduced mortality. But they also highlighted a crucial timeframe - within six months of the last vaccine dose - when Case Fatality Risk (CFR) - the proportion of cases that resulted in death - was consistently at its lowest across all age groups. After this, the protective benefit of the vaccine began to wane and CFR increased.